Member

Parallel Bio


Parallel Bio offers end-to-end drug discovery services powered by scalable human immune organoids and a large diverse biobank. These include comprehensive drug discovery pipelines that progress from disease target identification to IND filing, human tissue-based preclinical testing and validation of therapeutics (as a "clinical trial in a dish" alternative to animal models), and personalized medicine analytics for patient stratification and precision insights. Parallel Bio also provides collaborative services for pharma partners, high-throughput compound testing on diverse human models, data generation and analytics from immune organoid systems, and support for AI-driven biological modeling to accelerate the right candidates toward the clinic.

Industries

N/A

Nr. of Employees

small (1-50)

Parallel Bio

1000 Marina Blvd. Ste 105, Brisbane, CA 94005


Products

A human tissue-based organoid system capable of modeling immune responses at scale, supporting diverse research applications and therapeutic development.

Data and analytics platform integrating high-resolution human biology data, powering drug discovery and precision medicine.


Services

End-to-end drug discovery service utilizing human biology models to progress from disease target identification to investigational new drug (IND) application.

Preclinical validation of therapeutics using human organoid and tissue models to inform clinical trial design and reduce animal testing.

Analysis of human-derived biological data to support stratified clinical approaches and precision medicine.

Expertise Areas

  • Human biology modeling
  • Drug discovery and development
  • Organoid technology
  • Precision medicine
  • Show More (3)

Key Technologies

  • Human immune organoids
  • Machine learning for biological data
  • Automation in experimental biology
  • High-throughput data generation
  • Show More (2)

Key People

Co-Founder & Co-CEO

LinkedIn

Robert DiFazio

Co-Founder & Co-CEO

LinkedIn

News & Updates

Parallel Bio featured among World Economic Forum's 2026 Technology Pioneers.

Feature on AI and organoids as alternatives to animal testing in drug development.

Coverage of Parallel Bio's fundraising and human immune organoid technology.

Discussion of the company's preclinical models using human tissue.

Overview of organoid technology for drug discovery.

Profile of Parallel Bio's approach and vision in drug development.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.